Physician profile
Jamil C Mohsin
NPI 1134158074
$7,542.88
in general payments reported to CMS, 2019-2025
30 companies · $1,017 in 2025
The $1,017 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,371 · 2020: $161 · 2021: $518 · 2022: $1,013 · 2023: $2,626 · 2024: $837 · 2025: $1,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,564 · Travel and Lodging: $916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,564.06 |
| Travel and Lodging | $915.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,201.48 | 2019-2025 | Watchman Flx, Bodyguardian |
| Abbott Laboratories | $1,972.97 | 2019-2025 | Optis, Advisor, Jot Dx |
| Novartis Pharmaceuticals Corporation | $578.48 | 2021-2025 | |
| Amgen INC. | $277.98 | 2022-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $268.79 | 2020-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $217.14 | 2019-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $192.12 | 2025 | Uptravi, Opsumit |
| Tactile Systems Technology INC | $192.05 | 2021-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Merck Sharp & Dohme LLC | $187.48 | 2021-2023 | Verquvo |
| Shockwave Medical, INC | $172.20 | 2025 | |
| Esperion Therapeutics, INC. | $159.27 | 2021-2025 | Nexletol |
| Pfizer INC. | $156.31 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $145.79 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.35 | 2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.20 | 2020-2025 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $79.71 | 2023-2024 | Lifevest |
| Medtronic, INC. | $68.16 | 2022 | |
| Biosense Webster, INC. | $54.94 | 2023 | Carto 3 |
| Medtronic Vascular, INC. | $54.77 | 2019-2020 | |
| Cashflow Solutions, LLC | $44.13 | 2022-2025 | Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt |
| Amarin Pharma, INC. | $41.31 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $40.43 | 2019-2024 | Praluent, Evkeeza |
| Lexicon Pharmaceuticals, INC. | $37.85 | 2024 | |
| Arbor Pharmaceuticals, INC. | $33.14 | 2021 | |
| Inspire Medical Systems, INC. | $31.19 | 2023 | Inspire |
| Genzyme Corporation | $29.48 | 2023 | |
| Cardiva Medical, INC. | $22.76 | 2022 | |
| Scpharmaceuticals INC. | $19.49 | 2024 | |
| Sanofi-Aventis U.S. LLC | $16.09 | 2021 | |
| Siemens Medical Solutions USA, INC. | $13.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamil Mohsin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.